Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Product Portfolio > Late Stage

Products in Late Stage DevelopmentSpectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Spectrum has two late-stage drug candidates including Captisol-enabled™ melphalan, a new IV formulation of melphalan that has the potential to offer multiple advantages for clinicians and patients in the multiple myeloma transplant setting and apaziquone, a synthetic bio-reductive agent being investigated in the treatment of non muscle-invasive bladder cancer.

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company


spectrum pharmaceuticals products